C WorldWide Group Holding A S Has $5.74 Million Stake in Teva Pharmaceutical Industries Limited (TEVA)

C WorldWide Group Holding A S lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 30.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 326,269 shares of the company’s stock after acquiring an additional 76,038 shares during the period. C WorldWide Group Holding A S’s holdings in Teva Pharmaceutical Industries Limited were worth $5,742,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. San Francisco Sentry Investment Group CA purchased a new position in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter worth $106,000. Kistler Tiffany Companies LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the 3rd quarter worth about $129,000. Finally, Cutler Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter worth about $133,000. Institutional investors and hedge funds own 56.45% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “C WorldWide Group Holding A S Has $5.74 Million Stake in Teva Pharmaceutical Industries Limited (TEVA)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/11/12/c-worldwide-group-holding-a-s-has-5-74-million-stake-in-teva-pharmaceutical-industries-limited-teva.html.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down $0.07 during midday trading on Friday, reaching $11.78. The company’s stock had a trading volume of 16,789,900 shares, compared to its average volume of 29,309,564. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries Limited has a one year low of $10.85 and a one year high of $41.19. The stock has a market capitalization of $11,968.48, a PE ratio of 2.72 and a beta of 0.52.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date is Monday, November 27th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.80%.

TEVA has been the subject of a number of recent analyst reports. Credit Suisse Group set a $39.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective for the company in a research report on Monday, July 24th. Deutsche Bank AG reissued a “buy” rating and set a $28.00 price objective (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. BTIG Research raised Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Monday, September 11th. Finally, Gabelli reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, September 13th. Six research analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and a consensus target price of $23.26.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply